This tracker is no longer being regularly updated. There’s still a lot we don’t know including where. Updated 01 July with new information on Paxlovid, Evusheld, molnupiravir, Regkirona and ivermectin. Track each state’s progress as the US vaccination campaign gets underway. More doses have been administered than are showing up on the vaccine tracker. DelVAX is the source of the number of vaccine doses administered.
Among all Californians, 72.3 are fully vaccinated, meaning they have either received both shots of a two. Healthcare providers administering COVID vaccine are required to report vaccinations through the State's DelVAX Program.
Nytimes vaccine tracker series#
We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak. The Regional Vaccination Progress by New York Providers dashboard reflects all people vaccinated by New York providers. The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. Researchers are testing 38 vaccines in clinical trials on humans. Residency is self-reported by the individual being vaccinated. Whenever possible, we will describe how these therapeutics work against the dominant variants circulating throughout the world. So far, 79.9 of residents have received at least one dose, about 31.3 million people. The COVID-19 Vaccine Tracker: Vaccination Progress to Date dashboard shows all vaccinated individuals according to their county of residence.
Therapeutics that are effective against one version of the virus, for example, may be significantly less effective or even ineffective against a new variant. The New York Times made an eye-popping admission on Sunday regarding data collected by the Centers for Disease Control (CDC) on Covid-19 vaccines.In an article titled, 'The C.D.C. Regulators around the world have allowed many other additional treatments to be used on an emergency-use basis.Ī key ongoing focus in developing COVID-19 treatments will be the efficacy of therapeutics against current and emergent SARS-CoV-2 variants.
Evusheld (tixagevimab and cilgavimab AZD7442) has been authorized in several countries for use as pre-exposure prophylaxis. A handful of therapeutics have been approved specifically to treat COVID-19, reduce its severity, or prevent it entirely.Īs of July 2022, those treatments include dexamethasone, Avigan (favilavir), Veklury (remdesivir) alone and in combination with Olumiant (baricitinib), Lagevrio (molnupiravir), Xevudy (sotrovimab), Regkirona (regdanvimab), Ronapreve (casirivimab and imdevimab), amubarvimab and romlusevimab (formerly BRII-196 and BRII-198), Actemra/RoActemra (tocilizumab), Paxlovid (nirmatrelvir + ritonavir), and Kineret (anakinra). The New York Times has come out with a calculator that estimates how many people you're behind, based on where you live, if you have COVID-19 risk factors, occupation and age.